Stock Analysis of ARCA Biopharma Inc (ABIO) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ABIO
Close 1.84
Change 0.0100 / 0.546 %
Volume 19374.00
Vol Change 278.00 / 1.46 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Good Stability


Fundamental View of ARCA Biopharma Inc
PE (TTM)

-1493.39

Very Poor
Price / Book

164.46

Very Poor
Price / Sales

0

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

26514.58 K

Enterprise Value

-15930.42 K

ROA (TTM)

-10.58

Very Poor
ROE (TTM)

-11.01

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

48.63 %

-9926.00 K
Debt to Equity

0

Excellent
Altman Z Score

5.76

Excellent
Quick Ratio

0

Poor
Cash Ratio

37.50

Excellent


Highs/Lows of ARCA Biopharma Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.94 5.15 % 0.425 % 1.951.7828-Nov-2304-Dec-23
Two Week1.87 1.60 % 0.493 % 1.951.7828-Nov-2304-Dec-23
One Month1.9013 3.22 % 4.85 % 1.951.735928-Nov-2316-Nov-23
Three Month2.0588 10.63 % 1.20 % 2.07271.735115-Sep-2303-Nov-23
Six Months2.11 12.80 % 6.71 % 2.161.735116-Jun-2303-Nov-23
One year2.11 12.80 % 12.23 % 2.71.735106-Jan-2303-Nov-23
Two year2.25 18.22 % 0.691 % 2.271.735102-Mar-2303-Nov-23
Five year9.18 79.96 % 69.25 % 2.71.7106-Jan-2324-Jan-22
Ten year226.8 99.19 % 154.89 % 320.041.7108-Jan-1424-Jan-22


Technical View of ARCA Biopharma Inc
RSI

19.95

Mild Bullish
MACD

-0.0249

Bearish
ADX

34.99

Mild Bearish
Super Trend

2.06

Mild Bearish
Williams %R

-79.17

Mild Bullish
CCI

-310.44

Mild Bullish


EMA 5

1.94

Strong Bearish
EMA 15

1.99

Strong Bearish
EMA 50

2.02

Mild Bearish
EMA 100

2.04

Strong Bearish
SMA 100

2.04

Strong Bearish
SMA 200

2.07

Strong Bearish
SMA 5 / 20

1.95 / 2.01

Bearish
SMA 15 / 50

2.01 / 2.03

Strong Bearish
SMA 50 / 200

2.03 / 2.07

Mild Bearish




Charts of ARCA Biopharma Inc


Returns of ARCA Biopharma Inc with Peers
Period / StockABIOCDIOMTEMPPBT
1 Week-5.15%-36.73%-4.81%10.20%
1 Mth-3.22%281.94%-1.20%-16.28%
3 Mth-10.63%164.81%-41.83%-16.92%
6mth-12.80%0%947.40%-35.33%
1 Year-12.80%-32.55%870.59%-45.18%
2 Year-18.22%22.22%-71.20%
5 Years-79.96%0%5.10%-5.26%


Compare Fundamentals of ARCA Biopharma Inc with Peers
Ratio / StockABIOCDIOMTEMPPBT
PE-1493.39-1.83639.33-8.34
P/B164.463.78-25792.993.86
ROA-10.58-124.01159.18-40.58
ROE-11.01-207.000-46.42
Debt To Equity00-2.530.0041
Revenue0
% 		950.00
5.44 % 		19754.00 K
48.95 % 		-910000.00
184.38 %
Net Income-9926.00 K
48.63 % 		-4660.98 K
651.23 % 		92718.00 K
211.70 % 		-21668.00 K
17.86 %


Technicals of ARCA Biopharma Inc with Peers
Technical / StockABIOCDIOMTEMPPBT
ADX27.1248.0511.1418.65
CMF0.3430.159-0.107-0.066
MFI60.5590.8637.5260.36
RSI45.1350.6742.4747.73
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MAFalseTrueFalseFalse
Price Above 200 MAFalseFalseTrueFalse


About : ARCA Biopharma Inc

Address : 10170 Church Ranch Way, Westminster, CO, United States, 80021
Tel : 720 940 2200
URL : https://www.arcabio.com
Code : ABIO, ISIN : US00211Y5069, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 08_Aug_1997
Employee Count : 5

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.


Note : All Data Generated at the End of Trading Hours (EOD Data)